OverviewSuggest Edit

Tandem Diabetes Care is a medical device company that engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is primarily focused on manufacturing, sales, and support of its flagship pump platform, t:slim X2 Insulin Delivery System (t:slim X2), and complementary product offerings. Its hardware and software solutions and support services help people with diabetes and their healthcare providers improve diabetes therapy management.

TypePublic
Founded2006
HQSan Diego, CA, US
Websitetandemdiabetes.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2019)1,043(+60%)
Revenue (FY, 2020)$498.8 M(+38%)
Share Price (Feb 2021)$96 (+2%)
Cybersecurity ratingDMore

Key People/Management at Tandem Diabetes Care

Kim D. Blickenstaff

Kim D. Blickenstaff

Executive Chairman
Michael Fechko

Michael Fechko

Vice President, Manufacturing Operations
John F. Sheridan

John F. Sheridan

President and Chief Executive Officer, Director
David Berger

David Berger

Executive Vice President and Chief Legal & Compliance Officer
Elizabeth Gasser

Elizabeth Gasser

Executive Vice President, Strategy and Corporate Development
Tom Fox

Tom Fox

Vice President, Human Resources and Organizational Development
Show more

Tandem Diabetes Care Office Locations

Tandem Diabetes Care has an office in San Diego
San Diego, CA, US (HQ)
11075 Roselle St
Show all (1)

Tandem Diabetes Care Financials and Metrics

Tandem Diabetes Care Revenue

Embed Graph
View revenue for all periods
Tandem Diabetes Care's revenue was reported to be $498.83 m in FY, 2020
USD

Revenue (FY, 2020)

498.8m

Gross profit (FY, 2020)

260.5m

Gross profit margin (FY, 2020), %

52.2%

Net income (FY, 2020)

(34.4m)

EBIT (FY, 2020)

(8.0m)

Market capitalization (26-Feb-2021)

6.0b

Closing stock price (26-Feb-2021)

96.0

Cash (31-Dec-2020)

94.6m

EV

6.1b
Tandem Diabetes Care's current market capitalization is $6 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

107.6m183.9m362.3m498.8m

Revenue growth, %

28%71%97%

Cost of goods sold

63.5m94.0m168.1m238.3m

Gross profit

44.1m89.8m194.2m260.5m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q2, 2020Q3, 2020

Revenue

21.3m27.0m27.3m34.1m46.3m66.0m93.3m94.7m109.2m123.6m

Cost of goods sold

13.3m15.1m15.9m19.0m24.5m32.6m43.4m44.0m54.8m58.3m

Gross profit

8.0m11.9m11.4m15.1m21.8m33.4m49.9m50.7m54.4m65.3m

Gross profit Margin, %

38%44%42%44%47%51%54%54%50%53%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

44.7m13.7m41.8m51.2m94.6m

Accounts Receivable

11.2m20.8m35.2m46.6m82.2m

Prepaid Expenses

4.2m2.2m3.8m4.0m6.4m

Inventories

21.2m27.0m19.9m49.1m63.7m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q2, 2020Q3, 2020

Cash

40.3m27.4m12.1m62.6m50.5m32.3m40.4m38.2m46.1m222.5m129.5m

Accounts Receivable

7.7m9.0m10.6m13.0m13.9m21.7m33.0m48.4m45.3m45.0m52.1m

Prepaid Expenses

4.5m2.5m2.9m2.9m3.0m3.0m4.6m6.0m3.6m6.1m5.0m

Inventories

23.7m25.8m30.0m26.5m24.9m24.4m22.8m27.3m40.7m62.3m70.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(83.4m)(73.0m)(122.6m)(24.8m)(34.4m)

Depreciation and Amortization

5.5m6.9m5.8m6.1m10.5m

Inventories

(6.9m)(5.9m)6.8m(31.0m)(15.4m)

Accounts Payable

3.2m(2.0m)1.6m8.9m1.1m
Quarterly
USDFY, 2016

Debt/Equity

-13.3 x

Debt/Assets

0.7 x

Financial Leverage

-19 x
Show all financial metrics

Tandem Diabetes Care Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patents Issued

50 58 68 86

Patents Pending

46 49 68 68

Trademarks

23 23 23 39

Trademarks (Foreign)

13 13 13 23
Show all operating metrics

Tandem Diabetes Care Revenue Breakdown

Embed Graph

Tandem Diabetes Care revenue breakdown by geographic segment: 16.6% from International Sales and 83.4% from Domestic Sales

Tandem Diabetes Care Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

SecurityScorecard logo

Tandem Diabetes Care Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Tandem Diabetes Care Online and Social Media Presence

Embed Graph

Tandem Diabetes Care Company Culture

  • CEO Rating

    A+

    100/100

  • Compensation

    D

    55/100

Learn more on Comparably

Tandem Diabetes Care News and Updates

Thinking about trading options or stock in Tandem Diabetes Care, Revolve Group, Callon Petroleum, Vir Biotechnology, or T-Mobile?

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNDM, RVLV, CPE, VIR, and TMUS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Should you invest in Tandem Diabetes Care, Appian Corp, Novavax, Royal Caribbean Cruises, or Boeing?

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNDM, APPN, NVAX, RCL, and BA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

lobal Artificial Pancreas Systems Market Report 2019 Top Key Players- Medtronic, Johnson and Johnson, Dexcom, Insulet, Tandem Diabetes Care and more...

A new market study, titled “Global Artificial Pancreas Systems Market Report 2019 - Market Size, Share, Price, Trend and Forecast”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Tandem Diabetes Care, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, June 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). If...

Tandem Diabetes Care Frequently Asked Questions

  • When was Tandem Diabetes Care founded?

    Tandem Diabetes Care was founded in 2006.

  • Who are Tandem Diabetes Care key executives?

    Tandem Diabetes Care's key executives are Kim D. Blickenstaff, Michael Fechko and John F. Sheridan.

  • How many employees does Tandem Diabetes Care have?

    Tandem Diabetes Care has 1,043 employees.

  • What is Tandem Diabetes Care revenue?

    Latest Tandem Diabetes Care annual revenue is $498.8 m.

  • What is Tandem Diabetes Care revenue per employee?

    Latest Tandem Diabetes Care revenue per employee is $478.3 k.

  • Who are Tandem Diabetes Care competitors?

    Competitors of Tandem Diabetes Care include Apria Healthcare Group, Acelity and Neurometrix.

  • Where is Tandem Diabetes Care headquarters?

    Tandem Diabetes Care headquarters is located at 11075 Roselle St, San Diego.

  • Where are Tandem Diabetes Care offices?

    Tandem Diabetes Care has an office in San Diego.

  • How many offices does Tandem Diabetes Care have?

    Tandem Diabetes Care has 1 office.